Beactica Therapeutics Overview
- Year Founded
-
2006
- Status
-
Private
- Employees
-
16
- Latest Deal Type
-
2ndary - Private
- Investors
-
6
Beactica Therapeutics General Information
Description
Developer of a medicine discovery platform designed to facilitate the treatment of glioblastoma and other cancers. The company's platform offers protein-based therapeutics that regulate the expression of disease-associated proteins in order to change the chromatin configuration that governs the regulation of deoxyribonucleic acid transcription and improve the immune system's ability to fight cancer, enabling medical practitioners to treat patients with cancer with improved efficiency and lower risks.
Contact Information
Website
www.beactica.comCorporate Office
- Uppsala Business Park
- Rapsgatan 7
- 754 50 Uppsala
- Sweden
Corporate Office
- Uppsala Business Park
- Rapsgatan 7
- 754 50 Uppsala
- Sweden
Beactica Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 11. Secondary Transaction - Private | 01-Apr-2026 | Completed | Generating Revenue | |||
| 10. Later Stage VC | 01-Jan-2021 | Completed | Generating Revenue | |||
| 9. Later Stage VC | 01-Jan-2020 | Completed | Generating Revenue | |||
| 8. Grant | 18-Jun-2019 | Completed | Pre-Clinical Trials | |||
| 7. Later Stage VC | 04-Jun-2019 | Completed | Pre-Clinical Trials | |||
| 6. Grant | 23-Mar-2018 | Completed | Pre-Clinical Trials | |||
| 5. Later Stage VC | 15-Dec-2014 | Completed | Pre-Clinical Trials | |||
| 4. Accelerator/Incubator | Completed | Pre-Clinical Trials | ||||
| 3. Grant | 20-Nov-2014 | $407K | Completed | Pre-Clinical Trials | ||
| 2. Grant | 14-Sep-2007 | $187K | Completed | Pre-Clinical Trials |
Beactica Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary | ||||||||
| Ordinary |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Beactica Therapeutics Comparisons
Industry
Financing
Details
Beactica Therapeutics Competitors (100)
One of Beactica Therapeutics’s 100 competitors is TOLREMO therapeutics, a Venture Capital-Backed company based in Basel, Switzerland.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| TOLREMO therapeutics | Venture Capital-Backed | Basel, Switzerland | ||||
| Numerion Labs | Venture Capital-Backed | San Francisco, CA | ||||
| Biosceptre | Venture Capital-Backed | Cambridge, United Kingdom | ||||
| Cellestia | Venture Capital-Backed | Basel, Switzerland | ||||
| Plexium | Venture Capital-Backed | San Diego, CA |
Beactica Therapeutics Patents
Beactica Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2024277772-A1 | Aromatic amides and conjugates thereof as binders to tead | Pending | 24-May-2023 | ||
| EP-4720044-A1 | Aromatic amides and conjugates thereof as binders to tead | Pending | 24-May-2023 | ||
| WO-2024240840-A1 | Aromatic amides and conjugates thereof as binders to tead | Inactive | 24-May-2023 | C07D223/12 |
Beactica Therapeutics Signals
Beactica Therapeutics Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| SWElife | Government | |||
| Flerie | Venture Capital | Minority | ||
| M2Capital | PE/Buyout | Minority | ||
| Paab | Venture Capital | Minority | ||
| Unionen | Corporation | Minority |
Beactica Therapeutics FAQs
-
When was Beactica Therapeutics founded?
Beactica Therapeutics was founded in 2006.
-
Where is Beactica Therapeutics headquartered?
Beactica Therapeutics is headquartered in Uppsala, Sweden.
-
What is the size of Beactica Therapeutics?
Beactica Therapeutics has 16 total employees.
-
What industry is Beactica Therapeutics in?
Beactica Therapeutics’s primary industry is Drug Discovery.
-
Is Beactica Therapeutics a private or public company?
Beactica Therapeutics is a Private company.
-
What is Beactica Therapeutics’s current revenue?
The current revenue for Beactica Therapeutics is .
-
How much funding has Beactica Therapeutics raised over time?
Beactica Therapeutics has raised $2.61M.
-
Who are Beactica Therapeutics’s investors?
SWElife, Flerie, M2Capital, Paab, and Unionen are 5 of 6 investors who have invested in Beactica Therapeutics.
-
Who are Beactica Therapeutics’s competitors?
TOLREMO therapeutics, Numerion Labs, Biosceptre, Cellestia, and Plexium are some of the 100 competitors of Beactica Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process